Additional treatment after liver transplant for high-risk liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving additional treatment after a liver transplant can help prevent liver cancer from coming back in people who are at high risk for recurrence. The treatment is given shortly after the transplant and aims to improve outcomes for patients with aggressive liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had a liver transplant within the past 4 to 8 weeks.
- You have a confirmed diagnosis of hepatocellular carcinoma (the most common type of liver cancer) and it is considered high risk (for example, it was large, involved blood vessels, or had satellite nodules).
- You have not had systemic anti-cancer treatment before the transplant, except for TACE, traditional Chinese medicine, or interferon.
- Your liver function is good (Child-Pugh A) and you are otherwise in fairly good health (ECOG 0-1).
- If you have hepatitis B, you will continue antiviral therapy after the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding a targeted therapy (lenvatinib) to standard chemotherapy after a liver transplant can help prevent liver cancer from coming back. It may be an option for patients who have had a transplant and want to reduce the risk of recurrence.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.